Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8036125 | 0.79 | CYP2C9 (0.64) | GAACYP2C9PKMCYP3A4POLB | |
| SCHEMBL4285704 | 0.78 | ALDH1A1 (0.50) | CYP2C9CYP3A4POLBKDM4EHPGD | |
| SCHEMBL27895440 | 0.75 | MEN1 (0.58) | GAACYP2C9PKMCYP3A4POLB | |
| SCHEMBL4288230 | 0.75 | LMNA (0.65) | PKMKDM4EHPGDMEN1KMT2A | |
| SCHEMBL16704245 | 0.74 | MEN1 (0.57) | GAACYP2C9PKMCYP3A4POLB | |
| SCHEMBL3998201 | 0.74 | GAA (0.58) | GAACYP2C9PKMCYP3A4POLB | |
| SCHEMBL1878446 | 0.73 | TDP1 (0.57) | GAACYP2C9PKMCYP3A4POLB | |
| SCHEMBL16504785 | 0.72 | OPRK1 (0.43) | GAAPOLBMEN1KMT2A | |
| SCHEMBL21960399 | 0.72 | MEN1 (0.56) | GAACYP2C9PKMCYP3A4POLB | |
| SCHEMBL7452281 | 0.72 | MEN1 (0.56) | GAACYP2C9PKMCYP3A4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | GAA 2871/4885CYP2C9 508/4885PKM 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.